Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the EGFR antibodies cetuximab and panitumumab are approved for the treatment of patients with colorectal cancer. However, a major clinical challenge is a short-term response owi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2015
Konular:
Translational Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4651123/
https://ncbi.nlm.nih.gov/pubmed/26372697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller